Table 1

Baseline demographic and clinical characteristics

Optimal therapy at discharge (n/N)Suboptimal therapy at discharge (n/N)p ValueNo or one drug at discharge (n/N)
Age (median, 25, 75th percentile)(66.3; 56.9; 75.1) (1977)(70.5; 60.9; 79.1) (3166)<0.001(73.2; 63.8; 81.1) (314)
Male (%)69.7% (1378/1977)63.7% (2019/3169)<0.00163.4% (199/314)
Type of ACS
STEMI (%)54.6% (1022/1871)53.8% (1644/3058)0.55558.3% (176/302)
NSTEMI (%)45.4% (849/1871)46.2% (1414/3058)0.55541.7% (126/302)
Concomitant risk factors
Nicotine (%)38.9% (766/1968)29.9% (944/3157)<0.00124.9% (78/313)
Hypertension (%)70.6% (1389/1968)63.1% (1993/3157)<0.00155.3% (173/313)
Dyslipidaemia (%)55.0% (1082/1968)37.5% (1184/3157)<0.00124.9% (78/313)
Diabetes (%)28.6% (563/1968)29.6% (934/3157)0.45430.7% (96/313)
Concomitant disease
Previous MI (%)21.0% (416/1977)19.8% (629/3172)0.29320.4% (64/314)
Previous stroke (%)5.7% (112/1977)8.7% (276/3172)<0.00111.5% (36/314)
Previous PAD (%)6.9% (136/1977)9.0% (286/3172)0.00712.1% (38/314)
Previous CABG (%)7.7% (152/1977)5.1% (163/3172)<0.0015.4% (17/314)
Medication before event
Aspirin (%)37.6% (743/1977)31.9% (1013/3172)<0.00129.3% (92/314)
Clopidogrel (%)4.5% (89/1977)3.4% (108/3172)0.0463.2% (10/314)
β-blockers (%)36.7% (726/1977)29.6% (938/3172)<0.00125.2% (79/314)
RAS-blocking agents (%)34.1% (674/1977)28.2% (893/3172)<0.00124.5% (77/314)
Statins (%)22.5% (444/1977)13.2% (420/3172)<0.00110.2% (32/314)